Sacubitril + Valsartan 50mgTablet
Cardiac & Anti-Coagulant

Sacubitril + Valsartan 50mg

Sacubitril + Valsartan

First-in-class ARNI combining neprilysin inhibitor with ARB for heart failure with reduced ejection fraction, shown superior to enalapril in the PARADIGM-HF trial. Manufactured by Natco and Cipla for cardiology export.

Strengths

24/26mg / 49/51mg / 97/103mg

Packing

28 tablets/pack

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Sacubitril 24mg + Valsartan 26mg (50mg) / Sacubitril 49mg + Valsartan 51mg (100mg)
Dosage Form
Tablet
Available Strengths
24/26mg / 49/51mg / 97/103mg
Packing
28 tablets/pack
Route of Administration
Oral, with or without food
Dosage
Start 49/51mg twice daily; double dose every 2-4 weeks to target 97/103mg twice daily
Indications
Heart failure with reduced ejection fraction (HFrEF), NYHA class II-IV
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 30°C, protect from moisture
Shelf Life
36 months
Side Effects
Hypotension, hyperkalemia, cough, dizziness, renal impairment, angioedema
Precautions
36-hour washout from ACEi before starting; angioedema risk; monitor renal function and potassium; contraindicated in pregnancy; do not use with ACE inhibitors

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Metoprolol Succinate 50mgTablet

Metoprolol Succinate 50mg

Metoprolol Succinate

Cardioselective beta-1 adrenoceptor blocker in extended-release formulation that reduces heart rate, blood pressure, and myocardial oxygen demand with once-daily dosing for hypertension, stable angina, and heart failure with reduced ejection fraction. Manufactured to USP standards by Sun Pharma and Cipla and exported globally as a key cardiovascular agent in hypertension, post-MI, and heart failure management protocols.

25mg / 50mg / 100mg
Losartan 50mgTablet

Losartan 50mg

Losartan Potassium

Selective AT1 angiotensin II receptor blocker (ARB) that reduces blood pressure, protects renal function in diabetic nephropathy, and decreases cardiovascular events in hypertensive patients with left ventricular hypertrophy, with a tolerability advantage over ACE inhibitors due to the absence of bradykinin-mediated cough. Manufactured by Cipla and Sun Pharma and exported globally as a widely-used first-line antihypertensive and renoprotective agent.

25mg / 50mg / 100mg
Ramipril 5mgTablet

Ramipril 5mg

Ramipril

Long-acting ACE inhibitor with demonstrated cardiovascular risk reduction benefits across hypertension, post-MI left ventricular dysfunction, chronic heart failure, and diabetic nephropathy, supported by landmark HOPE and REIN trial data. Available in four strengths from Sanofi and Cipla for stepwise titration, exported globally as a cornerstone RAAS agent in both primary and secondary cardiovascular prevention protocols.

1.25mg / 2.5mg / 5mg / 10mg

Need bulk pricing for Sacubitril + Valsartan 50mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote